Suppr超能文献

甲癣局部治疗的最新进展。

Recent progress on the topical therapy of onychomycosis.

作者信息

Alley Michael R K, Baker Stephen J, Beutner Karl R, Plattner Jacob

机构信息

Anacor Pharmaceuticals, 1060 East Meadow Circle, Palo Alto, CA 94303, USA.

出版信息

Expert Opin Investig Drugs. 2007 Feb;16(2):157-67. doi: 10.1517/13543784.16.2.157.

Abstract

Onychomycosis is a fungal infection of the fingernails and toenails that results in thickening, discoloration, splitting of the nails and lifting of the nail from the nail bed. The disease is caused by dermatophytes and has a high incidence within the general population, especially among older individuals. Present treatment options include both oral and topical drugs, with oral therapies giving better outcomes; however, neither of these treatment options provides high cure rates that are durable. The difficulty in treating onychomycosis results from the deep-seated nature of the infection within the nail unit (nail plate, nail bed and surrounding tissue) and the inability of drugs to effectively reach all sites. Ongoing drug development activities have focused on novel delivery technologies to facilitate penetration of existing antifungal drugs through the nail plate and on the discovery of inherently penetrable antifungals. AN-2690 represents an oxaborole antifungal that is designed to penetrate the nail plate and is showing promising results in clinical trials.

摘要

甲癣是一种手指甲和脚趾甲的真菌感染,会导致指甲增厚、变色、裂开以及指甲与甲床分离。该疾病由皮肤癣菌引起,在普通人群中发病率较高,尤其是在老年人中。目前的治疗选择包括口服和外用药物,口服疗法效果更佳;然而,这些治疗选择都无法提供持久的高治愈率。治疗甲癣的困难源于感染在甲单位(甲板、甲床和周围组织)内的深层性质以及药物无法有效到达所有部位。正在进行的药物研发活动集中在新型给药技术上,以促进现有抗真菌药物穿透甲板,以及发现具有内在穿透性的抗真菌药物。AN - 2690是一种硼酸硼烷类抗真菌药物,旨在穿透甲板,并且在临床试验中显示出有前景的结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验